- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03576170
Investigate the Efficacy and Effectiveness of Aromatherapy for the Management of Behavioral and Psychological Symptoms of Dementia
In recent decades, following an increased longevity in Hong Kong, there is a drastic increase in the prevalence chronic conditions, including dementia. Behavioral and psychological symptoms of dementia (BDSP) seem to be the main reasons of suffering for many older adults. This condition does not only pose a burden to the whole family but also the healthcare system.
While conventional treatment of BPSD using pharmacotherapy and non-pharmacological treatments has been effective for managing symptoms, owing to the adverse side effects caused by anti-psychotic drugs and the short effective period incurred by non-pharmacological interventions, development of alternative and non-pharmacological approaches for the management of behavioral disturbances and pain is of urgent need. Research has shown that aromatherapy (both administered through inhalation and therapeutic massage) has been effective in reducing behavioral disturbances of dementia patients. These findings support the premise that aromatherapy and the investigators hope to provide further evidence to support the use of aromatherapy as an evidence-based mainstream intervention for reducing behavioral and psychological symptoms of dementia (BPSD).
Whilst there is sufficient evidence to support the effectiveness of aromatherapy, few studies compared the effectiveness of the use of aromatherapy by inhalation and/or therapeutic massage. The investigators aim to address the above research gaps on the clinical application of aromatherapy on BPSD, with a focus on comparing the differential effectiveness between administration by inhalation and administration by therapeutic massage. The proposed research aims to (1) test the efficacy and effectiveness of aromatherapy on the symptom management of BPSD in older adults; (2) compare the effects of aromatherapy-scent (i.e., inhalation) and aromatherapy-touch (i.e., therapeutic massage) in older adults with BPSD. This study also explores the benefits of aromatherapy on cognitive functioning, functional performance and social engagement as secondary outcomes.
A randomized, controlled, and single blinded trial is proposed. 120 older adults with BPSD will be randomly assigned to aroma inhalation (intervention), aroma-touch or wait-list (control) treatments. The primary outcomes measured are a caregiver-rated inventory of agitated behaviors and abnormalities of mood and psychotic phenomenal, cognitive functioning, functional performance and social engagement (secondary outcome) will be assessed three time points the study hypotheses are supported, the findings will provide empirical support for a treatment option that could improve psychological well-being and also improve cognitive functioning, functional performance, and social engagement of older adults.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hong Kong, Hong Kong
- The Hong Kong Polytechinic University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 60 years of age or older
- have a CMMSE score below 18 if illiterate, 19 if they have 1-2 years of education, and 20 if they had more than 2 years of education
- reported to have BPSD;
- willing to participate in the research, with informed consent signed by their guardian or carer.
Exclusion Criteria:
- allergic to essential oils
- refused to give consent
- over-sensitive to tactile stimulation
- have a history of kidney and liver disease
- have ever had an epileptic seizure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: aromatherapy-scent
|
aromatherapy by inhalation and/or therapeutic massage
|
ACTIVE_COMPARATOR: aromatherapy-touch
|
aromatherapy by inhalation and/or therapeutic massage
|
NO_INTERVENTION: wait-list control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chinese Version of the Cohen- Mansfield Agitation Inventory (CMAI)
Time Frame: baseline, 2-months after intervention and after the completion of the intervention in four months
|
It is a care-giver rated inventory to assess agitation in elderly persons and records the frequency of occurrence of BDSP at different period of time and thus can be used for assessing the changes among three times points (baseline, 2-months after intervention and after the completion of the intervention) in four months.
It includes descriptions of 29 agitated behaviors, and each is rated on a 7-point scale of frequency.
The total scores range from 29 points to 203 points, a higher score of CMAI indicates more frequent agitation behaviors.
|
baseline, 2-months after intervention and after the completion of the intervention in four months
|
Chinese Version of the Neuropsychiatric Inventory (NPI)
Time Frame: baseline, 2-months after intervention and after the completion of the intervention in four months
|
It is used to assess the changes of the abnormalities of mood and psychotic phenomena among three times points (baseline, 2-months after intervention and after the completion of the intervention) in four months.
If the response to the domain question is "No", the informant goes to the next question.
If "Yes", the informant then rates both the Severity of the symptoms present within the last month on a 3-point scale and the associated impact of the symptom manifestations on them (i.e.
Caregiver Distress) using a 5-point scale.
The NPI-Q provides symptom Severity and Distress ratings for each symptom), and total Severity and Distress scores reflecting the sum of individual domain scores ranging from 0 to 36 and ranging from 0 to 60 respectively.
|
baseline, 2-months after intervention and after the completion of the intervention in four months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cantonese Version of the Mini-mental State Examination (CMMSE)
Time Frame: baseline, 2-months after intervention and after the completion of the intervention in four months
|
Cantonese Version of Mini-mental State Examination (MMSE) is a brief 30-point questionnaire used to assess the change of the cognitive functions among three time points (baseline, 2-months after intervention and after the completion of the intervention) in four months.
The range of the score is from 0 point to 30 points, which a lower score indicates the worse cognitive functions.
|
baseline, 2-months after intervention and after the completion of the intervention in four months
|
Chinese Version of the Barthel Index-100
Time Frame: baseline, 2-months after intervention and after the completion of the intervention in four months
|
Chinese Version of the Barthel Index-100 is used to measure the change of the performance in activities of daily living (ADL) among three time points (baseline, 2-months after intervention and after the completion of the intervention) in four months. Scores range from 0 to 100, with higher scores indicating greater independence. of performance in basic activities of daily living (BADL) which is sensitive to either decline or improvement on the functional level of the elderly |
baseline, 2-months after intervention and after the completion of the intervention in four months
|
Chinese Version of the Index of Social Engagement(ISE)
Time Frame: baseline, 2-months after intervention and after the completion of the intervention in four months
|
The change of the social engagement among three time points (baseline, 2-months after intervention and after the completion of the intervention) in four months will be measured using the 6-item index of social engagement (ISE).
Total scores on the ISE can range from 0 to 6, with a higher score indicating a higher level of social engagement.
|
baseline, 2-months after intervention and after the completion of the intervention in four months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P17-0203-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityRecruitingDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeRecruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityRecruitingDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Cognito Therapeutics, Inc.Enrolling by invitationExtension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Dementia Alzheimers | Dementia of Alzheimer Type | AD | Dementia, Mild | Dementia ModerateUnited States
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
-
Karen RobertoNational Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Neuro-Degenerative Disease | Dementia of Alzheimer Type | Dementia SevereUnited States
-
University College, LondonNot yet recruitingDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal | DEM
-
University College, LondonThe University of Hong KongUnknownDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal
-
Karolinska InstitutetRegion Stockholm; KTH Royal Institute of TechnologyActive, not recruitingAlzheimer Dementia | Dementia DisordersSweden
Clinical Trials on aromatherapy
-
Tokat Gaziosmanpasa UniversityCompleted
-
Franklin Health ResearchCompletedMorning Sickness | Pregnancy EarlyUnited States
-
Chung Shan Medical UniversityRecruitingAnxiety Depression DisorderTaiwan
-
The Hong Kong Polytechnic UniversityCompleted
-
Ataturk UniversityCompleted
-
KTO Karatay UniversityNot yet recruiting
-
Ege UniversityCompleted
-
Franklin Health ResearchCompletedAnxiety | Autism Spectrum DisorderUnited States